N
Google TrendARSENAL (5000+) — Arsenal v Lille: Champions League – live
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:arsenal5000+anthony gordon500+montez sweat2000+rob lowe1000+tanner hudson500+frozen frenzy200+huevo1000+payton pritchard1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "ASCO 2026: Multiple Myelo" (30 stories)

Top Headline Story

ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field
Lead StoryThe ASCO Postgeneral
Jul 25

ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxObkd1cTlZdXR0ZWJ3NzZpU2hRUTYzcndnYWlTQnhpSk96QmJfdk82OW50aU8xR2NZLUFMRXlvT3pGQkEtMjFPdDc0Q1lMNUZoZ3FETDlROUxzOERQSERwY0U3MWgwLWV6OXZJZ0xobWpXcnhOVF96VGx5YXVWUHNVNk03OWRlT1hKbWRnWERQSVI5Smh2OVZjZ1l4T1NLVlFsZHJSVw?oc=5" target="_blank">ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+15m ago

arsenal

Arsenal v Lille: Champions League – live

Filter stories
500+15m ago

anthony gordon

Anthony Gordon's first Barcelona goal, Manuel Neuer's mistake and Djed Spence's Inter debut in the Euro Debrief

Filter stories
2000+25m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories
1000+35m ago

rob lowe

Ben Shapiro’s Star-Studded ‘Confession’ Film Includes James Franco, Rob Lowe And More

Filter stories

Search Results for "ASCO 2026: Multiple Myelo"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
“One of the Best Myeloma Sessions I’ve Ever Been to”: Highlights From ASCO 2026
Oncology News Centralgeneral

“One of the Best Myeloma Sessions I’ve Ever Been to”: Highlights From ASCO 2026

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPTGNTS3VJdjY1RU5MWVV2TS12eGFCVFJMNVVWV3lsQTY1c1JlZ0hQQnBqLXIwam4wVGJKRWtiYnpvTml5bnlwSFVKSkFWUkFveXdSS1JCcTdUM08tcG9fTzFxOERkT1l2UHJqTmV4MWk4TGoxM2VyMkg1R0NESjNxLUxwZmJOWmtCQnZyYWUxRjIwS3luaW9yOUpidlQwQ0RGQTJNMHpUNEVLSTZ2WXFHUks0alZyUS1KV1hhd1RaQ2pYdW5uNDkwUjBMXzB2QUU?oc=5" target="_blank">“One of the Best Myeloma Sessions I’ve Ever Been to”: Highlights From ASCO 2026</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Key Findings in Multiple Myeloma From ASCO 2026
Medscapegeneral

Key Findings in Multiple Myeloma From ASCO 2026

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQcHNTbEFVNVNReHgwcUx2SHl5RzdvSlFNeS1BSWxNZEJVRDBSaHdrU2c4ZEkwdm43N1JEbVZSbTRYQ0toekxUNnZsZ2R6ZVJ3QTZia19SenFmYURiSzVzWV9LeWFKRHFhZ2lMSlZ6Z3lBdEVHWlM5YVh0TzF2X3VWUXY4MmZTSDQ4Z0RyUHRqX2M?oc=5" target="_blank">Key Findings in Multiple Myeloma From ASCO 2026</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
CancerNetworkgeneral

ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPWERuT0JIM3cweWdEeEsxbm12U3hycDNKeEN2WUR6VGs1TkhKQ1BpZmFrU0x5cWRXaUlOSFlId0xiSURSVjBXZEdJSVBGSWo2eGd1QlJ6YjU3LUtyNGJoeTFDVUhLQy1nZ1o4LUxfdG1OUDdHRFM2V1dfaEpqUWhCVk8tQUlEWFNiV3hicVYzcHZET0dNZktNNXNVUlREYlVwUnltZlVvOVpheXZV?oc=5" target="_blank">ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Tecvayli Boosts Survival in Relapsed Multiple Myeloma: MajesTEC-9 Trial
Cure Todaygeneral

Tecvayli Boosts Survival in Relapsed Multiple Myeloma: MajesTEC-9 Trial

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNcjNNZG5OMnVCNDhiTVdpdTNrZUxaQ0FuODE3UXRzOVdyaUtKTUlIVmxVSG5LdzB5T3ZxRFhwbEV5bUkwelBXY1VRb0RqNzFJeFFwRnZDaldJNV9XVWUzamRZU3dSUFFXQ18xNmctYkhqck1fZHA5Skp6TjN6bXhsand5aVZmYm9RZkx4dkdpbDRfVExFU2NNQmg2Q2lKTWxoUGFN?oc=5" target="_blank">Tecvayli Boosts Survival in Relapsed Multiple Myeloma: MajesTEC-9 Trial</a>  <font color="#6f6f6f">Cure Today</font>

Read Full StoryMore like this
NEJM/ASCO: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma in landmark international trial
EurekAlert! Science News Releasesgeneral

NEJM/ASCO: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma in landmark international trial

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9KUEtveC1QRW1sT052bG5QQ1lBSkNLM3hXdFZ4WFJfdkZjWXgxQmtnRUIzUmRqX21JT256VjUxVzh5VVo2R0JRZFhSdkVhZFdhTEVjdUFKcl9uWTM1?oc=5" target="_blank">NEJM/ASCO: Teclistamab extends survival, deepens remissions in relapsed multiple myeloma in landmark international trial</a>  <font color="#6f6f6f">EurekAlert! Science News Releases</font>

Read Full StoryMore like this
Recent Findings From MajesTEC-3, CARTITUDE-4 Trials Spur Update to ASCO’s Living Guideline on Treatment of Relapsed/Refractory MM
ASCO Daily Newsgeneral

Recent Findings From MajesTEC-3, CARTITUDE-4 Trials Spur Update to ASCO’s Living Guideline on Treatment of Relapsed/Refractory MM

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQLWRXUXlZT3VtN3FxODMzNWlvcVpyWjJaVHVPQy1rZXB1Nm5TQ3ItcUhlQUlSZXV0T001MmVzQmZnRXJUa2Y1eWkteE9Bb1RWd2V5Yi14UVlfSnRNYUNmdVZhTFdxb1FOQlJ2UmdCQWhBX2RHbDctMl9MTnhHRlBCaWlncWVEeGVlakFtMEZVd001bVhoa2l2TEpmdzBnZE9ERXFDd2VKQTlKRmFFcHJtN20yUTF5UQ?oc=5" target="_blank">Recent Findings From MajesTEC-3, CARTITUDE-4 Trials Spur Update to ASCO’s Living Guideline on Treatment of Relapsed/Refractory MM</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026
OncLivegeneral

Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOYXNVWWRXWFZ0RmYwOVNRdUd6dUxIMlVHOXVkXzBSWTJyc3NJaWJsTm9teGFpLWxDeDZDUkxUQ0Z5aWdrakpPN2dLMFY2cnNBandHLW1TWVdHWjlGa0ZHc3NUWEpGVDFURUl2SHNLeHN6eTd0Y0ROWTBuUjhENGsxaFFCOFF2TTF2VUh6cEZmTkhucXR5cG1uZjhuMElkbl9TeXhzYUhOdUVVSEhqV2c0Mm5HUmg1Q194MHJR?oc=5" target="_blank">Teclistamab Monotherapy Tops SOC PVd/Kd in Myeloma, With Phase 3 Data Presented at ASCO 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
ASCO 2026: Mary Steinbach, DNP, APRN, Shares Top Myeloma Highlights
Cancer Nursing Todaygeneral

ASCO 2026: Mary Steinbach, DNP, APRN, Shares Top Myeloma Highlights

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVnNDdmR6eExhdU5veUYtR3JPQjNxYjIxVHBOUmtLZzdVZVdfdzJBWDRldWcwa1M1QWltb0k0VUZvLVV3OERLM1RBdnNESWc4aS1aajg5TFhvRkswTWVMVmhiN2ZyaUtmN2ZFXzhnamMwN2ViXzJCUFFWV0FKbEc5OG11Zm9VQl80WENlclo2OWFFbC1nems3U1R5bVpXNGVjQ3p5RzM0NEw?oc=5" target="_blank">ASCO 2026: Mary Steinbach, DNP, APRN, Shares Top Myeloma Highlights</a>  <font color="#6f6f6f">Cancer Nursing Today</font>

Read Full StoryMore like this
“It’s a Really Great Time for Myeloma”: Results at ASCO 2026 “Push the Envelope”
Oncology News Centralgeneral

“It’s a Really Great Time for Myeloma”: Results at ASCO 2026 “Push the Envelope”

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPS1VSNFI1TW5kSHVvUkVpQUctcmlIejdaYWh0WlBIczNLaFg2YWdXWllkVHJ4bjMxcV8yZzgwLXQ3N0cxdjFmenVMSlRvNGFWSmwxc1VjZE12eUstUVRxa3NRR29iVGpOd1pTUm5acFlGRHlRenZDdWVVUUJJMG1qNU1NZF9uak81ckl2blNpcWI2YmFvUkk4RkcwLXVZVkJsZUFDb2lyQWRwaWhlbzVnUHEtVXFsSGNQTjhUMEFsX3Q1WFA5UENGcHdGaUk1dw?oc=5" target="_blank">“It’s a Really Great Time for Myeloma”: Results at ASCO 2026 “Push the Envelope”</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab
The ASCO Postgeneral

Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOcVpPRDg1c2psMEFkQTdUc2ZyRW9CbVltMWV2V0hOUlpHN1dGQWVBd0daN2xzX3Y2bW1iMDdCRUpnZ1Y4TEFJOEQtZVJtcDRNZW1kN3lQOGV4Z2U0TmdSTXVBd2ZNMmpBVERXZm5BUDdadWpPUDdSRGw0WWtPVVBHZ09qeU9ZZzc5N0RNR2FTVlhPenV4QkR1V2NyZUJGRk5aZEE?oc=5" target="_blank">Relapsed or Refractory Multiple Myeloma: Talquetamab/Daratumumab</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Hematologists Highlight Top Data From ASCO 2026
OncLivegeneral

Hematologists Highlight Top Data From ASCO 2026

<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPaFFkRTdUcmZ0WGZjbUZfX0ZJcEEtclVLR1lWX18tQjg3TlltU3Q4Rk13U2ZrSVc5SHhUOUN1SFlRR1pWLThUUE55QjQ1MTVVelZ5NmpOTnZmeHBUeVBfTkFMS2FybjFxTU9EY1ZnZlZiUFhwaXJzSEF1Wjd2LVNNWnRR?oc=5" target="_blank">Hematologists Highlight Top Data From ASCO 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
ASCO Publicationsgeneral

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTFBCOHl3LUNyN0NDZzJhc3phTVpZNTUyV1lRamh6blZXeTQ2ZmhIR3NjenF4c0RTM0Q2MnRVa3JVVDZXam5LT3ZwSGc1dW40SnBQeDU5MTdwUjV2eEE?oc=5" target="_blank">High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy</a>  <font color="#6f6f6f">ASCO Publications</font>

Read Full StoryMore like this
ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment
The ASCO Posttech

ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQZVAyalQzYlBudDIxZktRSW1lOWxfTHVKbEFnX3BFNWk1RmsyY0NPOHZ0ZWdMOENNSGRzRWVzV0k1OXdlZWtFMEFSaVJlQ29wT01WNGUtVDVMaDlZWThJeEtraktGemxBT18td1MwVlJockRUWGtlR2d4ZE1BUDlEQkJ0YTVPTGE3V3VJdnJiY2h4aUR3ZmU3OFkwd1JlZ2RUd29aTkdHdWtwdG5oYVNaUi1HdVJwUndyNk92SEJxQmZVRVVQeUt2b2Y4V3ZfYVRwLTJlZjBDYTEyYVhnSHk2cUhDMTFvdw?oc=5" target="_blank">ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite vs 2 Years of Maintenance Treatment</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Polls Reveal Picks for Top Hematologic Oncology Abstracts at ASCO 2026
OncLivegeneral

Polls Reveal Picks for Top Hematologic Oncology Abstracts at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPUEt5VzBXMGYybUtzNHRzTndXWk4zVFVXOHRqQ1oybGtYMEJBQTk5NDdFR2J3bGRDT3VrZnhidnZNMml2c19qVmtZdk9tclJjVW52bllQcXVDbWdlN0NUc0JXMDV5c2pmTUhlcTVvZzQ1ZmFSNF9qMDdZcVdCbm5PTG05d3RPN2dSQWRHcHpUNWNGTmpOb3FvaFdEZWVzWXZY?oc=5" target="_blank">Polls Reveal Picks for Top Hematologic Oncology Abstracts at ASCO 2026</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma
Oncology News Centralgeneral

“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQUGlDZ29wVFRwLWpFM3ViNVRPYjQxTXNYT3JPelc5Ylp5cDRwdlBsd0ROa2xzTzUxRXlyVjV1eFFFd0tjTEFoN2xTaHlfU2R1aXNHRl9Ba0pNblZIbDJLcmNsalU0Ym9qc1pXdE95NzYwVUJkRTk3T28tRjN6ZUhUU0x6ZXJzMFY2cnVWVkx4U3JhT2NlZU5lMTMtYy1WZE91NzF6d0VuRWJqZGRrQnVhbnRjeFE1SW1weFNGMg?oc=5" target="_blank">“Massive Shift” Prompts ASCO to Update Guideline for Multiple Myeloma</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant
The ASCO Postworld

Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOcUZGNTNPaVVRR21rNmtuYnlBVzlnV0F1WVJ3STdlOFJuRnF5UFllRlVHOWhENTFuSWxVTWhWVFpiVVJ3UklhLTJwaHRhWXkwWHZHYzVSN0tmdFhHVFNjNkRoVF94LVljLXdWbVRvcmg0NVplR3ZDaGtwR0hKNUxrSV9kdXgwcWRZN1BscFNpVWVLdjlEWDIxSFBlNS16dm1Jb1RGdkxXT281bGs4bWFpbmxDNmdta1RqdTA4el92MU54VmEzd3NLTllGOGJwdGVGS2RKNjhhbXdxTGtUYkJpOWsyUDlyNDQ?oc=5" target="_blank">Defining Functional High-Risk Multiple Myeloma in the Era of Quadruplet Therapy and Autologous Stem Cell Transplant</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
The ASCO Postgeneral

FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQc3NTVllBbFBOWWJaMHRrRGdkemZHMkNCd19tU013SWd4dTF0cHlsUkEwaGFjQ3pzZDVlYzdkWkppTEVNaW5IRl9yOUYzZkZsU1dhRkV6SXFLRlZjMEFXUDBBSXlMYjdiUnJVRWVBb0ZIVk5PUUg0d3BhT2h6Y0t4dDdnMEdDNkYwN1Q0ODZ6V191ZU05SGdQV0ozUFdmdmh0aHplNXJmRzYxR3JFVGNn?oc=5" target="_blank">FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma
The ASCO Postgeneral

Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMkpRZGdfejRsYUNBXzE0a2VYdlZuaDBBN2l1NHZxODF4U3ZwWWZ0RFhXNHlUVUpoVFh5QTV4TWdpM25IOXB0Sk43TUJXX1JOVHJuVGtOY2Vram1aX01MbHJsazVvTFplVXhCUExVRWh4QWxNcmlZLWpFWDZ6YnRnRVp3cVJSUUw2Rk5IYkxfVWVkd1VIeWZrRjVPWW5TbEFFU0JQMG0zSm5NOGtPUjNOejYzeDZlSmhwbkVleWZFbzNnQkd6dkZZdElwTFpRbm5VUVE?oc=5" target="_blank">Teclistamab Improves Progression-Free and Overall Survival in Previously Treated Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Teclistamab in Previously Treated Multiple Myeloma
The ASCO Postgeneral

Teclistamab in Previously Treated Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxNRW5ZQVp0NVNwVksyRmhTTXY2a1lHU2xlNWhYOFRNVnd1aG9kTHdZam9SeExBWkVhN0NKdGZGTVR5dHI0MFp4SEZKSkFXY2VTU0hqMDZZRHhMSEFjejF6Vnl6bmdqMzdFdmlWTV9ReGtoZDY5dExwaEhMU1JVZktzTElPYVg3RHB6RjkxbDJISXg?oc=5" target="_blank">Teclistamab in Previously Treated Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
The ASCO Postgeneral

Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNLXZlaVJtLWttc2pYaTNLX0RzYjg0a3dxakhUdGZlbFhCVUtVZjFOMUd3bG9hMzdYTWM2TkJUX21nUldJdFZzQ25hcHJrbUo2S3JvZ1pMWHUzOVV6OVRoY0tRenpVMVZ6dk4xMWxnUmJqR1VicVRIbFlFckYwSDlVUDRUZnhLMXFWcHVNRGt3Qlc1TVVZTEp1WlBxTnk5RmxWTkZ1bmFObnNfYXd6bUl3d2NYRnAyNU1MdTYzN0NsWE9OQWdZLWFVNkVScTQ1UQ?oc=5" target="_blank">Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma
OncLivegeneral

Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQOU5LRFEwV3VMZ2lTXzZKR0d5RFRZWFlBQkQ3QlpaRnNGRDY4YWhORjZhSTFYZW0zVTV5ZlZmckFZQ1g5YUtVdFZ0V1B5ZEdSVklvMDVncl85ZEFuREZ1NXR0SkpZX01lV3A2SHZJYjlyaXRRRUJiWW96SFY0aFc1UkNKQTNicXI2bGJPVlYtOEViZFNpclhvMQ?oc=5" target="_blank">Previewing ASCO 2026: SUCCESSOR-2 Trial in R/R Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
The ASCO Postgeneral

Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQU0pESnJZQlE2czlUNDQtV1ZRVkdLZzQ5dkVYZVpJeDFDTm5MWDU2b2dSTkEzaVpFYlI3T191c1FOUlNDUzd3dkhfcE8wQmh0bjNadWd4U3dfdWhwVmIwVHFYc0tGdWtHRVRhSFhMb1RnMEFGX08yb2tlc2hsRU5BMnQwR1VuVXpHQk1zMmg1VWhSbC1JeFAwN2N3ZkFVTF90MFh2bUpYQXZuZG5nVWFTNzEyMVlMaGd1YThrTDBVNzEyalpCb2w4aC1mQQ?oc=5" target="_blank">Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Optec/Optal: Dr. Forsberg Highlights Key Multiple Myeloma Research Considerations at ASCO 2026
Cancer Nursing Todaygeneral

Optec/Optal: Dr. Forsberg Highlights Key Multiple Myeloma Research Considerations at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQSTNnT3pFdDE0eVNsYUpzWTRNTUFBLW50YTZWMEFoWnp2cXZLXzA4VlZoVnJfRGxhWm1BOEh4X05rMjRrREh3V0ZBSDNOZ29IM2F5UXgyWUh6Uzc4YlZCSzBFYURybW8wWkxyME1nZjhGelphQ29nWjFnVGhxdWVGMkYzVS1fYVQ2WkRvcHpqck9GZUduSlpxMllnTFo3bHRWTXhPdzF2X3BDWFdieU5sZ01NOWo0WVB2aGJOM1lDS3BpM3dYWUFhMkdGbW91eHYwZ0JCajZxVHlHaW54alVHYmlFcW0?oc=5" target="_blank">Optec/Optal: Dr. Forsberg Highlights Key Multiple Myeloma Research Considerations at ASCO 2026</a>  <font color="#6f6f6f">Cancer Nursing Today</font>

Read Full StoryMore like this
ASCO 2026: New AI Tool May Help Personalize Multiple Myeloma Treatment | Newswise
Newswisetech

ASCO 2026: New AI Tool May Help Personalize Multiple Myeloma Treatment | Newswise

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOaG92VEg0WkNkV0lXZm4tU01vLUVrOGU0MURhbzBqNVNZcGozY1VPcEJiRFFMN2g4ZjRhODNYcWdpSDZoeEtSUzZkWE5WT1F5WU9FVUlMaG9zV0xLU3pyUDhQRlhURmtmWjV5TlBsdVhWa1hfOVNGQVg1emUxdnZacDl6WEJFLWV0clZYLW9uWVQ1NHJIN280ZEZSOVlHRURubTVfNWN30gGmAUFVX3lxTE5ob3ZUSDRaQ2RXSVdmbi1TTW8tRWs4ZTQxRGFvMGo1U1lwajNjVU9wQmJEUUw3aDhmNGE4M1hxZ2lINmh4S1JTNmRYTlZPUXlZT0VVSUxob3NXTEtTenJQOFBGWFRGa2ZaNXlOUGx1WFZrWF85U0ZBWDV6ZTF2dlpwOXpYQkUtZXRyVlgtb25ZVDU0ckg3bzRkRlI5WUdFRG5tNV81Y3c?oc=5" target="_blank">ASCO 2026: New AI Tool May Help Personalize Multiple Myeloma Treatment | Newswise</a>  <font color="#6f6f6f">Newswise</font>

Read Full StoryMore like this
Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma
The ASCO Postgeneral

Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPR0dhay02RkNsaDhZYlNKSmtpR0hPcGxidGVZUS1ob2E5algwSkQ0T2dUenpXYlhuYy1QdV8tdDhNOHpsYnY3X3ZuZ1h3MU1wMGRCc2NWOUszYTZRTGwyZEdxSFY5cHlGQlVLd0tNRVU1VzM4elkxSldRbkdfcHNMQ2lrWHFYLXQ4REh1WGgtZlJMeDJGUWp1ZEMzS0hqX1pEdGhxd2pMdXBKeHY4NF9tSFdwbnF3VUxzdklvcFctbDNjQVN0X3RUbE1YZmpQYVRieDM0TU9ubmQxVEE2dnc?oc=5" target="_blank">Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
Fierce Biotechgeneral

ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPNzBxNS1tYVhNbGN6RU5lQWowMzZzWE9ZT2VmaGlIN3k4U1gyMTlZc2ZpTWJpZEtzaHFaY0RVNWRxWWR6aGRDemtXUzZ4SVJrRmprdkUyQncyYUVKMlM1Y3J0bHJXOHlkSVNhWVVtenJmQkhXdDBzSzdWaS0yX2FsY0oyal9lM3psUTdEaFhHX1FBWERUOThELWNEeHBHYm9pWDJz?oc=5" target="_blank">ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
The ASCO Postgeneral

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOYlF3R25lcV9JanBzS1JibHBKaUdRNnVDX0RpOHFPc1dBR19RRXVva0tXUHlSdTNZVjRuM2FjQ0tENnlScnNXVmtfRjVhTXFZYVllcWR0UnlEcmpkX2libG8zZncyRF9vRURDMFpzS3ZrZ2pSODdmNFNtWlIwbHFVZFJnM1kxYm90VmtiN2ZCV25oUC12MEJaUzhxbVFQcjZudEJsaE1Kc1NfZkxIWTVXTmY4MTF0ODNLdVJ0ckdDaXo?oc=5" target="_blank">High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Belantamab Mafodotin Associated With “Excellent” Outcomes in Multiple Myeloma
Cancer Therapy Advisorgeneral

Belantamab Mafodotin Associated With “Excellent” Outcomes in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOUnFieGJwUFNWcy0yZVRta21VOTh5WXJwSGI3ZVFpbHhZdndOMG00bGFPcGpXV09ZVldCWmJ6ckJJQ2g0VVgtbGctajJOdUtXRTdwNUJTbnRsWDBuQkw2TjY5bmhVZlNXNlNtNGw5alRtT0NiMzN5cnl5Z19MU3k1anowQ3lwUFB5WjB4WHdZVDVvUGg5Tm9mbTBBSV9ycE1DRFJzRA?oc=5" target="_blank">Belantamab Mafodotin Associated With “Excellent” Outcomes in Multiple Myeloma</a>  <font color="#6f6f6f">Cancer Therapy Advisor</font>

Read Full StoryMore like this
Unraveling Key Hematologic Oncology Developments at ASCO 2026
CancerNetworkworld

Unraveling Key Hematologic Oncology Developments at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOYVQyZUtYT3lkczJKSzhKNmpRc1RwdVRFSTlSNDZBUFpvQW95Ujk5RDV4MDAtNmJlV0lFNXJCcVZsSExfS3J4U0pEeXJuTFFBWHBORlo5bGFNR0dNTXptemZOX1pQc3I3WUZZTnNFMFlZY3paUGN0c09nREl6UnM5S196SGdmcDdieXpJT2VQMWFnd3ZPS0t6cnhQSms?oc=5" target="_blank">Unraveling Key Hematologic Oncology Developments at ASCO 2026</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
"ASCO 2026: Multiple Myelo" — Live Google News Trends & Headlines